In the 2012 edition of its Top 10 Fashion and Beauty Startups, Forbes.com ranked only one company, online retailer Mode-sty, above Personal Cell Sciences.  Personal Cell Sciences, a privately-held corporation, has brought to market “U Autologous,” a cutting-edge anti-aging skincare whose ingredients include a user’s own stem cells.  The crux of the recipe is pretty simple to grasp and easily understandable as to why it’s effective.  Adipose, or fat, stem cells are removed from a customer through liposuction, sent off for processing and Read More

Demographic trends towards an aging population, soaring diagnosis rates in diabetes, obesity and cardiovascular disease are just a few of the factors that are driving growth and spurring innovation to better serve millions of wound care patients each year.  The wound care industry has many verticals for sales, but probably none more critical than diabetic foot ulcers.  Diabetic foot ulcers affect about 15 percent of the nearly 26 million people with diabetes in the United States, and Read More

Broadly speaking, regenerative medicine is an innovative new area of medicine that is focused on the development of new therapies that enable healing and repair of the body in ways that overcome the limitations of conventional medical treatments.  Regenerative medicine uses a range of approaches, including cell based therapies, stem cells, tissue engineering and others, that represent Read More

An updated presentation for Excellagen has been published on the Cardium Therapeutics (NYSE MKT: CXM) website.  The pdf file is available for viewing/dowloading at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations. Read More

Cardium Therapeutics Ltd. (NYSE MKT: CXM), an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and business with the potential to address significant unmet medical needs and definable pathways to commercialization, similar to companies like Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR), said today that they have assembled a new Excellagen Medical Advisory Board as part of corporate initiatives Read More

Cardium to Present at the Rodman & Renshaw Annual 2012 Healthcare Investment Conference

Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J. Reinhard, Chairman & CEO will present at the Rodman & Renshaw Annual Healthcare Investment Conference on Monday, September 10, 2012 at 3:15 p.m. Eastern Time. The conference is being held September 9-11, 2012 at the Waldorf-Astoria Hotel in New York City. An audio webcast of the Company’s presentation will be available live and by replay and can be accessed at Read More

This morning, BioLife Solutions, Inc. (OTCBB: BLFS), reported results from operations for the second quarter ended June 30, 2012.  The Bothell, Washington-based developer, manufacturer and marketer of clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues posted quarterly revenue in excess of $1 million for the first time in company history and notched its eighth straight sequential of quarterly growth. Read More

Last year, industry specialist GlobalData released a report estimating the global diabetic foot ulcer therapeutics market to be valued at $1.15 billion in 2010 with expectations of growth to $2.28 billion by 2017.  A recent article by BBC News called today’s diabetic foot care “appalling” and leading to “an increased risk of having a foot amputated.”  With their Excellagen product, Cardium Therapeutics (NYSE MKT: CXM), a company in the same industry as Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR), Read More

Shares of Bioheart, Inc. (OTCBB: BHRT) rose to touch $0.0395 in Wednesday trading, their highest level since April 4. This morning, the Sunrise, Florida-based biotech released news that it received a non-binding term sheet and investment offer in the amount of $2 million from Grupo Vitalmex in Mexico, a provider of a variety of specialized and integrated services in the health care sector of Mexico and Europe. The specifics of the term sheet will be voted on by Bioheart’s Board of Directors on Monday, August 6, 2012, according Read More

It’s been a busy several weeks for Cardium Therapeutics (NYSE MKT: CXM) as industry attention and investor buzz continues to build around regenerative medicine companies. Generx®, Cardium’s flagship gene therapy product candidate, is a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease. In March 2012, Cardium initiated its Phase 3 registration clinical trial in Russia which is expected to enroll approximately 100 patients at up to eight leading cardiovascular centers. The San Diego Biotechnology Read More